Hold-rated reports

904 tickers rated Hold
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Waters Corporation
WAT·Healthcare
B ★★★Hold
Current$453.08
Target$472.50
Return+4.3%
Nov 6, 2026

Waters combines durable laboratory instrumentation, recurring consumables, and expanding diagnostics exposure with meaningful synergy opportunities, but elevated leverage and demanding cash-flow expectations limit its near-term investment appeal.

Score
68
MPLX LP
MPLX·Energy
B ★★★Hold
Current$56.55
Target$60.09
Return+6.3%
Nov 6, 2026

MPLX offers durable fee-based infrastructure cash flows and an attractive distribution yield, but its elevated valuation and capital-intensive growth program constrain the margin of safety.

Score
68
Ball Corporation
BALL·Consumer Discretionary
B ★★★Hold
Current$66.91
Target$71.84
Return+7.4%
Nov 6, 2026

Ball's global aluminum packaging franchise, improving comparable EPS, and disciplined buybacks support long-term value creation, but weak cash conversion, leverage, and a premium to packaging peers limit near-term upside.

Score
68
Expeditors International of Washington, Inc.
EXPD·Industrials
B ★★★Hold
Current$188.87
Target$180.81
Return-4.3%
Nov 6, 2026

Expeditors combines exceptional capital efficiency, global logistics relationships, and disciplined shareholder returns, but premium valuation and cyclical freight earnings limit its near-term risk-reward appeal.

Score
68
Marriott International, Inc.
MAR·Consumer Discretionary
B ★★★Hold
Current$424.87
Target$391.50
Return-7.9%
Nov 5, 2026

Marriott's global brands, loyalty ecosystem, and asset-light franchise economics support long-term earnings compounding, but elevated valuation multiples and meaningful leverage limit the margin of safety.

Score
68
Acadia Realty Trust
AKR·Real Estate
B ★★★Hold
Current$19.15
Target$22.10
Return+15.4%
Nov 5, 2026

Acadia Realty offers scarce urban retail assets, strong leasing spreads, and visible NOI growth, but leverage and equity dilution may prevent impressive property-level results from translating into equally strong per-share returns.

Score
68
Celanese Corporation
CE·Materials
B ★★★Hold
Current$49.75
Target$60.60
Return+21.8%
Nov 5, 2026

Celanese offers a cyclical earnings recovery and attractive normalized valuation supported by stronger cash flow, but substantial debt and volatile chemical margins constrain the investment case.

Score
68
CNA Financial Corporation
CNA·Financials
B ★★★Hold
Current$48.01
Target$51.60
Return+7.5%
Nov 5, 2026

CNA Financial offers an established commercial insurance franchise, substantial investment income, and attractive dividends, but weaker underwriting margins and legacy long-term care reserves constrain earnings reliability and upside.

Score
68
AbbVie Inc.
ABBV·Healthcare
B ★★★Hold
Current$289.00
Target$304.00
Return+5.2%
Nov 2, 2026

AbbVie's expanding Skyrizi, Rinvoq, and neuroscience franchises support durable earnings growth and dividends, but elevated valuation and dependence on patented therapies limit its margin of safety.

Score
68
WisdomTree, Inc.
WT·Financials
B ★★★Hold
Current$20.37
Target$24.30
Return+19.3%
Nov 2, 2026

WisdomTree combines strong organic AUM growth, scalable ETF economics and expanding alternative investment capabilities, but acquisition-related leverage and elevated historical valuation multiples limit the immediate margin of safety.

Score
68
Banco Santander-Chile
BSAC·Financials
B ★★★Hold
Current$31.48
Target$33.15
Return+5.3%
Nov 2, 2026

Banco Santander-Chile combines superior banking efficiency, strong ROE, and attractive shareholder distributions, but its elevated book-value multiple and deteriorating credit metrics limit the margin of safety.

Score
68
CNO Financial Group, Inc.
CNO·Financials
B ★★★Hold
Current$58.04
Target$62.40
Return+7.5%
Nov 2, 2026

CNO offers durable middle-income insurance demand, improving normalized returns, and meaningful buybacks, but its elevated historical valuation and exposure to actuarial and investment risks limit near-term upside.

Score
68